Investors Purchase High Volume of TG Therapeutics Call Options (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTXGet Free Report) was the target of unusually large options trading on Wednesday. Stock traders bought 18,866 call options on the company. This represents an increase of 122% compared to the typical daily volume of 8,484 call options.

Insider Buying and Selling

In related news, CFO Sean A. Power sold 47,867 shares of TG Therapeutics stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $16.91, for a total value of $809,430.97. Following the completion of the transaction, the chief financial officer now directly owns 606,969 shares of the company’s stock, valued at $10,263,845.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other TG Therapeutics news, Director Laurence N. Charney sold 17,500 shares of the stock in a transaction on Friday, January 5th. The stock was sold at an average price of $19.03, for a total value of $333,025.00. Following the transaction, the director now directly owns 237,229 shares in the company, valued at approximately $4,514,467.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Sean A. Power sold 47,867 shares of the business’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $16.91, for a total value of $809,430.97. Following the sale, the chief financial officer now owns 606,969 shares of the company’s stock, valued at approximately $10,263,845.79. The disclosure for this sale can be found here. 9.20% of the stock is owned by corporate insiders.

Institutional Trading of TG Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of TG Therapeutics by 13.3% in the third quarter. Vanguard Group Inc. now owns 14,746,392 shares of the biopharmaceutical company’s stock valued at $87,299,000 after buying an additional 1,725,560 shares during the last quarter. State Street Corp lifted its position in TG Therapeutics by 47.8% during the second quarter. State Street Corp now owns 14,235,263 shares of the biopharmaceutical company’s stock worth $60,500,000 after acquiring an additional 4,606,679 shares during the last quarter. Darwin Global Management Ltd. bought a new stake in shares of TG Therapeutics during the first quarter worth approximately $157,187,000. BlackRock Inc. grew its position in shares of TG Therapeutics by 12.1% in the second quarter. BlackRock Inc. now owns 9,917,463 shares of the biopharmaceutical company’s stock valued at $246,350,000 after purchasing an additional 1,067,763 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of TG Therapeutics by 5.6% during the second quarter. Geode Capital Management LLC now owns 2,830,589 shares of the biopharmaceutical company’s stock worth $70,312,000 after purchasing an additional 150,789 shares during the period. Institutional investors and hedge funds own 57.92% of the company’s stock.

TG Therapeutics Trading Down 2.3 %

Shares of NASDAQ TGTX opened at $17.22 on Friday. TG Therapeutics has a twelve month low of $6.46 and a twelve month high of $35.67. The stock has a market cap of $2.61 billion, a price-to-earnings ratio of -61.50 and a beta of 2.42. The company has a quick ratio of 4.95, a current ratio of 5.53 and a debt-to-equity ratio of 0.60. The company’s fifty day moving average is $15.95 and its 200-day moving average is $12.58.

TG Therapeutics (NASDAQ:TGTXGet Free Report) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.03. TG Therapeutics had a negative net margin of 13.65% and a negative return on equity of 35.58%. The firm had revenue of $43.97 million for the quarter, compared to the consensus estimate of $40.06 million. During the same period last year, the company posted ($0.39) EPS. Equities research analysts predict that TG Therapeutics will post 0.08 EPS for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on TGTX. StockNews.com cut TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 24th. B. Riley raised their price objective on shares of TG Therapeutics from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Monday, February 5th. HC Wainwright reiterated a “buy” rating and set a $45.00 target price on shares of TG Therapeutics in a research report on Wednesday. Finally, The Goldman Sachs Group raised their price target on TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Thursday. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $26.17.

Check Out Our Latest Research Report on TGTX

TG Therapeutics Company Profile

(Get Free Report)

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Featured Stories

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.